Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Share:
Related BMY
The Market In 5 Minutes: No Interest Rate Hike...Yet
Can You Guess This Chart?
Buy AbbVie Incorporated: Its Frustration Is Your Long-Term Gain (Seeking Alpha)
Related MRK
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen
Enrollment underway in Gemphire's mid-stage study of gemcabene in patients with inherited high cholesterol (Seeking Alpha)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
Sep 2016CitigroupMaintainsBuy
Sep 2016JefferiesMaintainsHold
Sep 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!